There are plenty of quality, high performing ASX shares.
Like online luxury goods retailer Cettire Ltd (ASX: CTT). The Cettire share price tops the leader’s board of big gainers on the All Ordinaries Index (ASX: XAO) in 2021, up a remarkable 618% year-to-date.
With that said, ASX shares make up only some 2% of the total global share market. So it’s worth considering looking beyond our shores to potential opportunities overseas.
But don’t just take my word for it.
According to The Motley Fool’s own Scott Phillips:
Investing internationally delivers tremendous portfolio diversification benefits and brings a world of opportunities to your investment doorstep.
And indeed, while the diversification benefits are very important, I actually think they run second to the sheer investment opportunities that exist overseas. Some of the very best companies on this blue and green planet aren’t on the ASX – so why would we limit ourselves to just our home market?
With that in mind, we take a look at 3 small-cap international shares tipped during yesterday’s ‘Bell Asset Management – Global equities market update and outlook for 2022’ webinar.
Looking beyond ASX shares
Ned Bell, Bell Asset Management’s chief investment officer, spearheaded the webinar.
On the buy side for the asset manager, he named 3 international shares that have come off their highs to be trading within Bell Asset’s buy level. Namely: Amedisys Inc (NASDAQ: AMED), GN Store Nord A/S (CPH: GN) and Intertek Group plc (LON: ITRK).
According to Bell:
GN, Intertek and Amedisys… are 3 names that we’ve been watching. We’ve owned Intertek before… They’ve been a little bit too expensive. We’ve been waiting from some earnings uncertainty and volatility to give us a buying opportunity. And that’s exactly what’s happened.
Those 3 names have come off their highs. They’ve got down to our buy levels, and that’s what triggered the buy here…
What these stocks all have in common, Bell added, “is that we’ve been patient on getting into them. And we think, looking ahead to the next 12-24 months, you’re going to get some P/E [price to earnings ratio] re-ratings.”
If you’ve been focused primarily on ASX shares you may not be familiar with these names.
In a nutshell:
Amedisys is a US healthcare company with a market cap of approximately US$5.4 billion. Shares finished up 4% yesterday but remain down 40% over the past 6 months.
GN is a Danish manufacturer of hearing aids and headsets. The GN share price finished up 1% yesterday and is down 24% over the past 6 months.
Intertek is a London-based global quality assurance provider. Shares finished flat yesterday and are down 20% over the past 6 months.